BIO vs VCYT: fair value comparison
Bio-Rad Laboratories, Inc. and Veracyte, Inc. · Updated 2026-08-31
BIO currently screens as overvalued while VCYT screens as fairly valued. Within Healthcare, VCYT currently sits closer to the top of our discount ranking. VCYT carries the stronger quality grade.
| BIO | VCYT | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $330.01 | $44.85 |
| 12-month range | $256.55–$334.71 | $30.11–$59.85 |
| Sector rank | #89 of 113 Healthcare | #85 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: BIO fair value analysis · VCYT fair value analysis